I don't understand your sense of humour. You try to be entertaining but you are not. The reported filing is real and this is what matters. If you live twice the next time try to be born in England. Maybe your sense of humor would improve.
Many are starting to realize, right now, that this science could be a real breakthrough. Frankly speaking, I am quite tired to see all those fashionable articles about immunotherapy, on "cosmopolitan " female magazine as well. None is talking about OXGN and VDA's and this makes this company so interesting.
Great disappointmentt the collapse from 2,67 to 1,40 in a fem momths, I used to belive in this company, but I think they are doing nothing to support the stock which is collapsing
Pfizer Inc (PFE) Reports 4.4% Position in Arqule Inc (ARQL)at Insider Monkey(Fri, Mar 18)
Indeed, ASCO this year can be very interesting
At 1,45 this stock is much undervalued. Ridiculous price considering the pipeline and the late stage tivatinib trials.
Probably the market was not expecting a stock offering, this is the reason why the stock is under pressure. But I think is a bargain inthe long term. This is a winning cancer technology
Indeed this is one of the cancer technologoes of the future. ARQL is very much undervalued at this level, cnsidering the pipeline. Ridiculous price
I am really glad about your interaction manofeconomics, you really one of the few able to express an articulate way of thinking, don't care so much about others in this forum. Bottom line is that still now for large solid tumors you won't be able to find good alternative clinical options and this company was able to produce remarkable clinical evidence in trials. Minus are extreme financial weakness and poor corporate direction. It is quite depressing to see that after soo many years they were not able to find a corporate partner able to fund the trials.This is not due to thefact that the technolgy is not working, but to idle management in my opinion. But all options are still open, company is still alive.
Apart from Falcon program for NSCLC, which turned out to be disappointing and abandoned, the rest of clinical results has not been bad at all. For ATC, they completed phase II successfully and got orphan drug desugnation in Europe, then suspended it, due to lack of funds. In march 2014 they reported remarkable results for ovarian cancer therapy. A 15 million dollars or less value for the company is simply ridiculous. Of course mangementedirection does not seem to be rational, and maybe this explains the current state of the thing, but I cannt say that they have not produced results as many think. That's all folks.
It was the mistake of many, mine as well. It is unbelivable the lack of confidence in this stock. Clinical data looks good to me an keeps falling every day. Rather puzzling, I have never seen a thing like this